Optimisation Of An Alp Assay In C2C12 Cells 20180618

Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

A method for optimising the amount of BMP-7 that needs to be added to the C2C12 myoblast cell line in order to increase the expression of alkaline phosphatase (as an indication of BMP signalling activity) sufficiently to be detected by using 4-methylumbelliferyl (4-MUP) as a fluorogenic substrate.

Related Organizations

University of Oxford
United Kingdom

Keywords

bmp signalling, c2c12, 4mup, 4-methylumbelliferyl, alp, alkaline phosphatase, optimization

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average